Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palatin

0.2179
-0.0001-0.05%
Post-market: 0.21790.00000.00%16:00 EDT
Volume:564.61K
Turnover:122.98K
Market Cap:6.13M
PE:-0.15
High:0.2239
Open:0.2154
Low:0.2096
Close:0.2180
Loading ...

BRIEF-Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide

Reuters
·
06 Feb

Palatin Technologies Inc - Topline Data Results Expected Later This Quarter

THOMSON REUTERS
·
06 Feb

Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide

THOMSON REUTERS
·
06 Feb

Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Jan

Strategic Focus on Obesity and Diversified Pipeline Drive Palatin Technologies’ Growth Potential

TIPRANKS
·
28 Jan

Palatin Provides Update on Anticipated 2025 Corporate Milestones

THOMSON REUTERS
·
28 Jan

Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

BRIEF-Palatin Announces Phase IIb Breakout Study Results In Patients With Type 2 Diabetic Nephropathy

Reuters
·
19 Dec 2024

Palatin reports positive Phase 2b results in diabetic nephropathy

TIPRANKS
·
19 Dec 2024

Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy

THOMSON REUTERS
·
19 Dec 2024

Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
19 Dec 2024

Palatin Technologies Signs Inducement Agreement for Gross Proceeds of $3.4 Million for Investor's Excercise of Warrants

MT Newswires Live
·
16 Dec 2024

Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Nov 2024

Buy Rating for Palatin Technologies: Promising Pipeline and Strategic Initiatives in Obesity Treatment

TIPRANKS
·
25 Nov 2024

Palatin completes patient enrollment in Phase 2 study of PL8177

TIPRANKS
·
25 Nov 2024

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist Pl8177 in Ulcerative Colitis

THOMSON REUTERS
·
25 Nov 2024

Q1 2025 Palatin Technologies Inc Earnings Call

Thomson Reuters StreetEvents
·
15 Nov 2024

Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...

GuruFocus.com
·
15 Nov 2024

Palatin Technologies Shifts Focus to Obesity Treatments

TIPRANKS
·
15 Nov 2024

Palatin Technologies: Strategic Focus on Obesity and Diversified Pipeline Justifies Buy Rating

TIPRANKS
·
15 Nov 2024